1. Home
  2. COUR vs DNTH Comparison

COUR vs DNTH Comparison

Compare COUR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coursera Inc.

COUR

Coursera Inc.

HOLD

Current Price

$8.45

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$44.22

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COUR
DNTH
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
COUR
DNTH
Price
$8.45
$44.22
Analyst Decision
Buy
Strong Buy
Analyst Count
11
10
Target Price
$12.36
$68.00
AVG Volume (30 Days)
2.4M
780.0K
Earning Date
10-23-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$739,774,000.00
$3,078,000.00
Revenue This Year
$10.46
N/A
Revenue Next Year
$6.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.09
N/A
52 Week Low
$5.76
$13.37
52 Week High
$13.56
$45.46

Technical Indicators

Market Signals
Indicator
COUR
DNTH
Relative Strength Index (RSI) 47.61 65.78
Support Level $7.83 $42.00
Resistance Level $8.00 $45.46
Average True Range (ATR) 0.26 2.00
MACD 0.12 0.13
Stochastic Oscillator 87.30 79.49

Price Performance

Historical Comparison
COUR
DNTH

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: